Read about the latest breakthroughs, awards and ongoing work from the SGC. Discover how our work is making a global impact and driving forward the field of drug discovery. Interested in getting first the latest news from SGC?
The Pfizer-SGC project aims to tackle a rare, hereditary metabolic disorder called homocystinuria, which leaves patients unable to metabolise the amino acid methionine. A team of researchers at Pfizer Rare Disease unit will work with Dr Wyatt Yue at the Structural Genomics Consortium at the…
Researchers from Oxford University, GlaxoSmithKline and Cellzome, as well as Memorial Sloan Kettering Hospital have developed and characterised the first selective inhibitor for a specific class of histone demethylases and demonstrated its utility in inhibiting proinflammatory cytokine…
Antibodies are first released in massive collaboration to create ‘master set’ of high-quality renewable epigenetics antibodies
TORONTO, June 4, 2012 – The Structural Genomics Consortium (SGC), a group of expert researchers in recombinant antibody technology from the…
Categories